SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO)

Historical Holders from Q3 2018 to Q4 2025

Type / Class
Equity / Common Stock, par value $0.001 per share
Symbol
STRO on Nasdaq
Shares outstanding
84,733,230
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares as of 30 Sep 2025
53,391,796
Total reported value
$46,361,876
% of total 13F portfolios
0%
Share change
-2,191,668
Value change
-$1,653,951
Avg buy value change
+0%
Avg sell value change
-0%
Number of holders
85
Price from insider filings
$8.02
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Affinity Asset Advisors, LLC 7.8% $5,717,348 6,583,772 Affinity Healthcare Fund, LP 16 Oct 2025
SUVRETTA CAPITAL MANAGEMENT, LLC 7.7% $4,632,014 6,488,324 Suvretta Capital Management, LLC 30 Jun 2025
MILLENNIUM MANAGEMENT LLC 5.6% $4,434,182 4,717,215 Millennium Management LLC 27 Jun 2025
VANGUARD GROUP INC 4.9% $2,937,877 4,115,250 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 2.5% -69% $1,493,679 -$2,892,242 2,092,281 -66% BlackRock, Inc. 30 Jun 2025
As of 30 Sep 2025, SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) has 85 institutional shareholders filing 13F forms. They hold 53,391,796 shares. of 84,733,230 outstanding shares (63%) .

Top 25 institutional shareholders own 59% of the company.

Filer Ownership Nb Shares Share Change % Portfolio % Holdings Value
SUVRETTA CAPITAL MANAGEMENT, LLC 7.7% 6,488,324 0% 0.17% $5,634,461
Kynam Capital Management, LP 6% 5,088,099 0% 0.33% $4,418,505
MILLENNIUM MANAGEMENT LLC 5.3% 4,524,350 -4.4% 0% $3,928,946
VANGUARD GROUP INC 4.3% 3,682,986 -11% 0% $3,196,832
ACADIAN ASSET MANAGEMENT LLC 4% 3,389,322 +11% 0.01% $2,941,000
Velan Capital Investment Management LP 3.7% 3,120,000 +2% 2.5% $2,709,408
TANG CAPITAL MANAGEMENT LLC 3.3% 2,828,717 +10% 0.09% $2,456,458
Merck & Co., Inc. 3.2% 2,723,509 0% 1% $2,365,095
Vestal Point Capital, LP 3.1% 2,600,000 0% 0.1% $2,257,840
Eversept Partners, LP 2.7% 2,291,313 -0.04% 0.15% $1,989,776
SAMSARA BIOCAPITAL, LLC 2.6% 2,196,814 0% 0.25% $1,907,713
ADAGE CAPITAL PARTNERS GP, L.L.C. 2.4% 2,000,000 0% 0% $1,736,800
UBS Group AG 2.2% 1,845,839 +14% 0% $1,602,188
BlackRock, Inc. 2% 1,687,880 -20% 0% $1,465,755
RENAISSANCE TECHNOLOGIES LLC 1.7% 1,424,797 +56% 0% $1,237,294
GEODE CAPITAL MANAGEMENT, LLC 0.97% 820,948 +0.49% 0% $713,188
Affinity Asset Advisors, LLC 0.89% 752,722 0% 0.06% $653,664
JACOBS LEVY EQUITY MANAGEMENT, INC 0.53% 445,750 0% $387,089
DAFNA Capital Management LLC 0.52% 437,079 0% 0.09% $379,559
TWO SIGMA INVESTMENTS, LP 0.47% 396,785 +245% 0% $344,568
AQR CAPITAL MANAGEMENT LLC 0.42% 354,449 -65% 0% $307,804
Fisher Asset Management, LLC 0.42% 352,949 0% 0% $306,500
STATE STREET CORP 0.4% 342,652 0% 0% $297,559
Shay Capital LLC 0.37% 312,051 +20% 0.05% $270,985
ROYAL BANK OF CANADA 0.31% 258,876 +17% 0% $225,000

Institutional Holders of SUTRO BIOPHARMA, INC. - Common Stock, par value $0.001 per share (STRO) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (% of par) Investors
2025 Q4 0 $0 -$40 0
2025 Q3 53,391,796 $46,361,876 -$1,653,951 86.84% 85
2025 Q2 55,585,121 $39,680,994 -$3,651,726 71.39% 100
2025 Q1 61,457,334 $39,985,859 -$10,841,219 65.06% 113
2024 Q4 63,895,959 $117,565,386 -$7,306,459 184% 122
2024 Q3 62,516,525 $216,373,636 -$1,660,759 346% 130
2024 Q2 63,167,394 $185,075,042 +$25,139,079 293% 119
2024 Q1 53,412,221 $301,719,025 +$2,094,339 565% 116
2023 Q4 55,648,249 $238,729,642 -$219,480 429% 113
2023 Q3 55,996,442 $194,308,615 +$5,622,550 347% 108
2023 Q2 54,105,078 $251,585,717 +$2,181,872 465% 119
2023 Q1 53,720,779 $247,499,715 +$10,470,599 462% 114
2022 Q4 49,984,035 $403,859,817 +$6,296,600 808% 116
2022 Q3 50,396,383 $279,697,401 +$23,514,794 555% 111
2022 Q2 46,245,672 $240,931,373 +$15,713,924 520.97% 111
2022 Q1 41,606,389 $341,990,813 -$38,514,469 822% 111
2021 Q4 39,677,298 $590,411,817 -$4,363,219 1,488% 114
2021 Q3 39,817,120 $752,214,523 -$26,368,206 1,888.97% 119
2021 Q2 41,241,047 $766,657,023 -$71,886,996 1,858.99% 121
2021 Q1 44,209,991 $1,005,487,689 +$114,863,310 2,276% 136
2020 Q4 39,392,744 $855,224,796 +$184,675,658 2,171% 132
2020 Q3 31,151,440 $313,088,624 +$67,545,691 1,005% 87
2020 Q2 23,997,579 $186,238,799 +$97,614,730 776% 76
2020 Q1 11,868,607 $116,270,683 +$7,872,102 1,019.99% 60
2019 Q4 11,616,437 $127,772,633 +$7,088,075 1,100% 64
2019 Q3 11,074,608 $91,621,057 -$8,301,817 908.98% 59
2019 Q2 11,817,484 $122,739,770 +$6,666,665 1,137.98% 58
2019 Q1 11,231,778 $116,185,606 +$4,727,906 1,138.85% 49
2018 Q4 9,707,399 $87,234,000 -$10,616,486 901.96% 41
2018 Q3 9,086,875 $135,767,000 +$129,306,000 1,500% 32